{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:57:50Z","timestamp":1772121470410,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.nucmedbio.2021.01.001","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:59:49Z","timestamp":1610567989000},"page":"53-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Towards the development of a targeted albumin-binding radioligand: Synthesis, radiolabelling and preliminary in vivo studies"],"prefix":"10.1016","volume":"94-95","author":[{"given":"Cathryn Helena Stanford","family":"Driver","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ebenhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoltan","family":"Szucs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Iqbal","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Rijn","family":"Zeevaart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/953537","article-title":"Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy","author":"Ting","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0010","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1016\/j.ccr.2005.03.005","article-title":"Targeting platinum anti-tumour drugs: overview of strategies employed to reduce systemic toxicity","volume":"249","author":"Van Zutphen","year":"2005","journal-title":"Coord Chem Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0015","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1016\/j.febslet.2014.02.005","article-title":"Deregulation of cell signaling in cancer","volume":"588","author":"Giancotti","year":"2014","journal-title":"FEBS Lett"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0020","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.addr.2010.10.008","article-title":"PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect","volume":"63","author":"Acharya","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0025","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","article-title":"Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect","volume":"71","author":"Maeda","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0035","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0040","first-page":"193","article-title":"Tumoritropic and lymphotropic principles of macromolecular drugs","volume":"6","author":"Maeda","year":"1989","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0169-409X(00)00134-4","article-title":"SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy","volume":"46","author":"Maeda","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0050","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41467-018-03705-y","article-title":"Progress and challenges towards targeted delivery of cancer therapeutics","volume":"9","author":"Rosenblum","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3390\/pharmaceutics9040046","article-title":"Targeting strategies for the combination treatment of cancer using drug delivery systems","volume":"9","author":"Kydd","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0065","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","article-title":"Therapeutic nanoparticles for drug delivery in cancer","volume":"14","author":"Cho","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0045","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1039\/c3cc41554f","article-title":"Tumour targeting with radiometals for diagnosis and therapy","volume":"49","author":"Ramogida","year":"2013","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0050","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","article-title":"Bifunctional coupling agents for radiolabelling of biomolecules and target-specific delivery of metallic radionuclides","volume":"60","author":"Liu","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0055","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S170879","article-title":"Copper-64: a real theranostic agent","volume":"12","author":"Gutfelin","year":"2018","journal-title":"Des Devel Ther"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0076-6879(04)86011-7","article-title":"Production and applications of Copper-64 radiopharmaceuticals","volume":"386","author":"Sun","year":"2004","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0065","first-page":"1","article-title":"The current status and future of theranostic Copper-64 radiopharmaceuticals","volume":"25","author":"Jalilian","year":"2017","journal-title":"Iran J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0070","doi-asserted-by":"crossref","first-page":"11908","DOI":"10.1039\/C8NJ00419F","article-title":"Optimization of the selectivity and rate of copper radioisotope complexation: formation and dissociation kinetic studies of 1,4,8-trimethylcyclam-based ligands with different coordinating pendant arms","volume":"42","author":"Paurova","year":"2018","journal-title":"New J Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/138161207779313768","article-title":"Copper chelation chemistry and its role in copper radiopharmaceuticals","volume":"13","author":"Wadas","year":"2007","journal-title":"Cur Pharm Design"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0080","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s10534-012-9578-y","article-title":"Development of copper based drugs, radiopharmaceuticals and medical materials","volume":"25","author":"Szymanski","year":"2012","journal-title":"Biometals"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0085","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/C5CS00158G","article-title":"Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy","volume":"45","author":"Liu","year":"2016","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0090","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2011.07.031","article-title":"Albumin-based nanoparticles as potential controlled release drug delivery systems","volume":"157","author":"Elzoghby","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0120","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","article-title":"Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles","volume":"132","author":"Kratz","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0960327107073825","article-title":"Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin","volume":"26","author":"Kratz","year":"2007","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0100","first-page":"99","article-title":"Albumin-bound formulation of paclitaxel (Abraxane\u00ae ABI-007) in the treatment of breast cancer","volume":"4","author":"Miele","year":"2009","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0105","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1021\/acs.bioconjchem.6b00487","article-title":"Albumin-binding Evans blue derivatives for diagnostic imaging and production of long-acting therapeutics","volume":"27","author":"Jacobson","year":"2016","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0110","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1021\/acs.bioconjchem.8b00919","article-title":"Bench to bedside: albumin binders for improved cancer radioligand therapies","volume":"30","author":"Lau","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0115","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1021\/acs.bioconjchem.7b00378","article-title":"Synthesis, radiolabeling, and characterization of plasma protein-binding ligands: potential tools for modulation of the pharmacokinetic properties of (radio)pharmaceuticals","volume":"28","author":"M\u00fcller","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0120","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pharmthera.2012.11.003","article-title":"The Warburg effect: insights from the past decade","volume":"137","author":"Upadhyay","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0125","first-page":"1038","article-title":"Targeting glucose transporters for tumor imaging: \u201csweet\u201d idea, \u201csour\u201d result","volume":"37","author":"Wahl","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0130","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006231-199802000-00002","article-title":"FDG uptake, tumour characteristics and response to therapy: a review","volume":"19","author":"Smith","year":"1998","journal-title":"Nucl Med Comm"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0135","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1002\/ejoc.201201457","article-title":"Carbohydrate-based molecules for molecular imaging in nuclear medicine","volume":"2013","author":"Morais","year":"2013","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7954854","article-title":"Nuclear imaging of glucose metabolism: beyond 18F-FDG","volume":"2019","author":"Feng","year":"2019","journal-title":"Contrast Media Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0145","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1021\/bc034038n","article-title":"Pyrophoephorbide 2-deoxyglucosamide: a new photosensitizer targeting glucose transporters","volume":"14","author":"Zhang","year":"2003","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/bc049774l","article-title":"Synthesis and in vitro characterization of organometallic rhenium and technetium glucose complexes against glut 1 and hexokinase","volume":"16","author":"Schibli","year":"2005","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0155","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-19-0691","article-title":"An activatable cancer-targeted hydrogen peroxide probe for photoacoustic and fluorescence imaging","author":"Weber","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0190","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1039\/b313659k","article-title":"Cyclam complexes and their applications in medicine","volume":"33","author":"Liang","year":"2004","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0195","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.addr.2004.01.004","article-title":"Folate-receptor-targeted radionuclide imaging agents","volume":"56","author":"Ke","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jinorgbio.2003.10.018","article-title":"Configurations of metallocyclams and relevance to anti-HIV activity","volume":"98","author":"Hunter","year":"2004","journal-title":"J Inorg Biochem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0170","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.nucmedbio.2009.03.007","article-title":"True radiotracers: Cu-64 targeting vectors based upon bombesin peptide","volume":"36","author":"Hoffmann","year":"2009","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0175","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1016\/j.bmcl.2010.07.114","article-title":"RGD-cyclam conjugates: synthesis and potential application for positron emission tomography","volume":"20","author":"Galibert","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0180","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.carres.2008.03.019","article-title":"Stereoselective glycosylations using benzoylated glucosyl halides with inexpensive promoters","volume":"343","author":"Murakami","year":"2008","journal-title":"Carbohydr Res"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0220","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cber.19801130922","article-title":"Synthesen mit Iod- und Bromtrimethylsilan in der Saccharidchemie","volume":"113","author":"Thiem","year":"1980","journal-title":"Chem Ber"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0225","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0008-6215(96)00321-7","article-title":"Mechanistic studies on the stereoselective formation of glycosyl iodides: first characterization of \u03b2-d-glycosyl iodides","volume":"300","author":"Gervay","year":"1997","journal-title":"Carbohydr. Res."},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0190","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1021\/acs.molpharmaceut.6b01010","article-title":"Preclinical comparison of albumin-binding Radiofolates: impact of linker entities on the in vitro and in vivo properties","volume":"14","author":"Siwowska","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0235","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1039\/b925703a","article-title":"Revival of TE2A: a better chelator for Cu(II) ions than TETA?","volume":"46","author":"Pandya","year":"2010","journal-title":"Chem Commun"},{"key":"10.1016\/j.nucmedbio.2021.01.001_rf0240","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/bc200539t","article-title":"New macrobicyclic chelator for the development of ultrastable 64Cu-radiolabeled bioconjugate","volume":"23","author":"Pandya","year":"2012","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0200","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1021\/bc400192a","article-title":"New bifunctional chelator for 64Cu-immuno-positron emission tomography","volume":"24","author":"Pandya","year":"2013","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10967-011-1301-x","article-title":"Studies on preparation of 64Cu using (n,\u03b3) route of reactor production using medium flux research reactor in India","volume":"290","author":"Vimalnath","year":"2011","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0210","series-title":"IAEA radioisotopes and radiopharmaceuticals reports no. 1","first-page":"3","article-title":"Cyclotron produced radionuclides: emerging positron emitters for medical applications: 64Cu and 124I","author":"International Atomic Energy Agency","year":"2016"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0215","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/molecules22040641","article-title":"Establishing reliable Cu-64 production process: from target plating to molecular specific tumour micro-PET imaging","volume":"22","author":"Xie","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0220","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1039\/b615329a","article-title":"Copper(ii) cyclam-based complexes for radiopharmaceutical applications: synthesis and structural analysis","volume":"9","author":"Silversides","year":"2007","journal-title":"Dalton Trans"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0225","doi-asserted-by":"crossref","first-page":"10157","DOI":"10.1039\/c3ra47302c","article-title":"Establishment of two complementary in vitro assays for radiocopper complexes achieving reliable and comparable evaluation of in vivo stability","volume":"4","author":"Zarschler","year":"2014","journal-title":"RSC Adv"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0230","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0969-8051(98)00017-1","article-title":"The in vivo behaviour of copper-64-labeled azamacrocyclic complexes","volume":"25","author":"Jones-Wilson","year":"1998","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0235","series-title":"Applied Pharmacology; Chapter 2: Pharmacokinetics","first-page":"17","author":"Bardal","year":"2011"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0240","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/IJGM.S102819","article-title":"Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements","volume":"9","author":"Levitt","year":"2016","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.nucmedbio.2021.01.001_bb0245","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.2967\/jnumed.114.144881","article-title":"PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates","volume":"55","author":"Beaino","year":"2014","journal-title":"J Nucl Med"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805121000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:29:52Z","timestamp":1760848192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805121000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"alternative-id":["S0969805121000159"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.01.001","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv.12687920.v1","asserted-by":"object"}]},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards the development of a targeted albumin-binding radioligand: Synthesis, radiolabelling and preliminary in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}